Figure 6. Combination of RET and ERK inhibitors is synergistic in RET-rearranged cells.

A and B. HMSC, HMSC-RET and SR-Sarc-0001 cells were treated with the indicated combinations of selpercatinib and ulixertinib (A) or selpercatinib and SCH772984 (B) for 96 h and then cell viability was determined. Loewe synergy analysis was applied to determine each combination synergy scores and their statistical significance. Resulting scores are shown as a contour map (top) or a matrix table (bottom).